This technology is an in vivo tissue-specific drug delivery system using tar
geted liposomes. It provides the following advantages: (1) Reduced toxicit
y, improved stability and solubility, prolonged circulation, increased drug
concentration in inflamed or tumor tissues, and enhanced safety. (2) Integ
ration of cell-recognition ligands on the carrier surface enables precise dr
ug release to target cells. This liposome delivers drugs to autophagic and
apoptotic cells and associated tissues, resulting in synergistic effects and i
mproved efficiency. Advantages include: (1) Pioneering and efficient in viv
o drug targeting system for damaged tissues without external guidance.
(2) Reduced side effects and dosage through precise targeting. (3) Innovat
ive drug platform for damaged tissues.
Precise targeting in drug delivery is trending, but limited in vivo applicabil
ity due to multifactorial diseases and drug resistance. A multi-target syste
m covering various tissues is urgently needed. Liposomal drug delivery is
mature with clinical trials, but multiple factors in cancer and chronic disea
ses require multiple injections and lead to resistance. To overcome this lim
itation, our team has focused on research and development. After extensi
ve efforts, we have successfully developed an innovative drug delivery car
rier with the following advantages:(1) It encapsulates diverse drugs (hydrophobic, hydrophilic, DNA, siRNA) f
or multiple indications.
(2) The targeting molecules possess multi-targeting capabilities (autopha
gic and apoptotic cells) and additional functions like anti-inflammatory an
d anti-hypoxia effects.
(3) It can be customized with single-target or synergistic-targeting molec
ules for different disease types.
(4) It can be combined with immune checkpoint inhibitors or other biologi
c therapies to optimize treatment strategies.